NCT 05927571
Brief Summary
The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II dosethe amount of medication taken (RP2D) for the study treatment. The study consists of a safety lead-in stage, and an expansion stage.
Intervention / Treatment
- Drug: Cevostamab
- Drug: Elranatamab
- Drug: Tocilizumab
Inclusion Criteria:
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) Performance Status of 0 or 1
- Diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of R/R MM per IMWG criteria
- For female participants of childbearing potential: agreement to remain abstinent or use contraception
- For male participants: agreement to remain abstinent or use a condom.